688065 Cathay Biotech Inc.
- 48.87
- -1.31-2.61%
Cathay Biotech Inc. News
Kaisai Biotech (688065): Promoting R&D investment and capacity building to accumulate growth momentum
The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 21.14 billion yuan, -13.39% year-on-year, and realized net profit of 367 million yuan, or -33.75% year-on-year.
Cathay Biotech (688065): Q1 main business performance inflection point, actively developing bio-based polyamide and piperidine businesses
Core view The company achieved significant improvements in revenue and profit margins in the first quarter, and downstream demand began to pick up; it is anticipated that subsequent sebacic acid projects will gradually expand as overseas customers develop, the Q1 inflection point will be established, and the company's performance growth will continue. Furthermore,
Cathay Biotech (688065): Demand recovery in 24Q1 is optimistic about capacity release+strategic cooperation to drive growth
Incident: The company released its 2023&2401 financial report on April 30, achieving revenue of 2,114 billion yuan in 2023, -13.39% year on year; net profit to mother of 367 million yuan, or -33.75% year on year. The company's intention
Kaisai Biotech (688065.SH): Using centralized bidding to buy back 929,500 company shares
Gelonghui, May 6 | Cathay Biotech (688065.SH) announced that as of April 30, 2024, the company had repurchased 929,464 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.1593% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 38.98 per share, and the total capital paid was RMB 48,418,430.17 (excluding transaction fees such as stamp duty and transaction commissions).
Cathay Biotech Inc.'s (SHSE:688065) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 18% Last Week
Key Insights Cathay Biotech's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 4 shareholders own 50% of the comp
Kaiser Biotech (688065): Demand is under pressure in 2023 24Q1 demand will improve significantly, and there is plenty of space for bio-based polyamides
Description of the incident On April 29, 2024, Kaiser Biotech released its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 2.114 billion yuan, a year-on-year decrease of 13.39%; achieved net profit to mother
Kaisai Biotech (688065) 2023 Annual Report and 2024 Quarterly Report Review: Q1 long-chain dibasic acid sales increased, profit increased significantly year-on-year
Event: On April 30, 2024, Kaiser Biotech released its 2023 annual report and first quarter report: achieved operating income of 2.114 billion yuan in 2023, a year-on-year decrease of 13.39%; achieved net profit to mother 3.
Kaisai Biotech (688065): 24Q1 performance, year-on-month recovery in demand for long-chain binary acid recovery
Incident: 1) The company achieved revenue of 2,114 billion yuan in 2023, -13.39%; realized net profit to mother of 367 million yuan, or -33.75% year on year; realized net profit after deduction of 307 million yuan, YoY-
Kaiser Biotech (688065): Significant increase in first-quarter results, imminent release of bio-based polyamides
Description of the incident On April 30, 2024, Kaiser Biotech released its 2023 Annual Report and 2024 Quarterly Report. The company achieved revenue of 2,114 billion yuan in 2023, a year-on-year decrease of 13.39%;
Cathay Biotech (688065): Demand for long-chain binary acids is picking up, Q1 performance is high year-on-month, and bio-based composites accelerate commercial application implementation
Key investment points: The company released its 2023 annual report: During the reporting period, the company achieved revenue of 21.14 billion yuan (YoY -13%), achieved net profit attributable to mother of 367 million yuan (YoY -34%), and achieved net profit deducted from non-mother 3
Cathay Biotech (688065.SH) announced first-quarter results, net profit of 105 million yuan, up 83.25% year-on-year
Cathay Biotech (688065.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Kaisai Biotech (688065): Q1 performance increased significantly over the same period last month and continued to advance
Core view The company achieved significant improvements in revenue and profit margins in the first quarter, and downstream demand began to pick up; it is anticipated that subsequent sebacic acid projects will gradually expand as overseas customers develop, the Q1 inflection point will be established, and the company's performance growth will continue. Furthermore,
Shareholders of Kaisai Biotech (688065.SH) Tianjin Sitong and Seasource reduced their holdings of the company by 1.1%
Cathay Biotech (688065.SH) issued an announcement. The company received the shareholder Tianjin Sitong on April 22, 2024...
Cathay Biotech's Q1 Profit to Surge Up to 100%, Revenue to Climb 43%; Shares Up 6%
Cathay Biotech (SHA:688065) expects to book a net profit attributable to shareholders of between 94 million yuan to 115 million yuan in the first quarter, climbing up to 100.2% from the year-ago profi
A-share changes丨Fa Yingxi, Kaisai Biotech rebounds 6.5%
Gelonghui, April 15 | Kaisai Biotech (688065.SH), which reached a record low last Friday, experienced a rebound. It has now risen 6.5% to 39.95 yuan, with a market value of 23.3 billion yuan. According to the news, the company's net profit for the first quarter was 94 million yuan to 115 million yuan, an increase of 63.65% to 100.20% over the previous year. During the period, sales volume and sales revenue of long-chain binary acids rose sharply compared to the same period last year. According to Shen Wan Hongyuan's research review, the company's demand for long-chain binary acids is picking up, and he is looking forward to commercializing the application of bio-based composites and maintaining the “gain” rating.
Cathay Biotech Inc.'s (SHSE:688065) Price Is Out Of Tune With Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 30x, you may consider Cathay Biotech Inc. (SHSE:688065) as a stock to avoid entirely with its 59.6x P/E ratio
Kaisai Biotech (688065) 24Q1 performance pre-increase review: 24Q1 gradually progresses towards positive fixed growth projects
Event: The company released its earnings forecast for the first quarter of 2024. Expected 24Q1 revenue of 650 to 720 million yuan, +28.60% to 42.45% year over year; net profit to mother is 0.94 to 115 million yuan, year on year+
Sudden! Gold Concept Stock Supervisor's Spouse Illegal Short-Term Tradings|Highlights of After-Market Announcements
Carmel Packaging: Net profit forecast year-on-year increase of 75.28% — 127.66% in the first quarter
Kaisai Biotech (688065.SH) increased in advance, with net profit of 94 million yuan to 115 million yuan in the first quarter, an increase of 63.65% to 100.20% over the previous year
Cathay Biotech (688065.SH) released a performance forecast for the first quarter of 2024. It is expected to achieve revenue of 650 million yuan to 720 million yuan in the first quarter of 2024, an increase of 28.60% to 42.45% over the previous year. Net profit attributable to shareholders of listed companies is expected to be between 94 million yuan and 115 million yuan in the first quarter of 2024, an increase of 63.65% to 100.20% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be 91 million yuan to 112 million yuan in the first quarter of 2024, an increase of 79.04 million yuan over the previous year
Kaisai Biotech: Net profit for the first quarter is expected to be 94 million yuan to 115 million yuan
Kaisai Biotech announced that the net profit for the first quarter is expected to be 94 million yuan to 115 million yuan, an increase of 63.65% to 100.20% over the previous year. The sales volume and sales revenue of long-chain dibasic acid have risen sharply compared to the same period last year.
Analysis
Price Target
No Data
